QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Public ClinicalTrials.gov record NCT01231347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas
Study identification
- NCT ID
- NCT01231347
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- NantCell, Inc.
- Industry
- Enrollment
- 800 participants
Conditions and interventions
Conditions
Interventions
- AMG 479 Drug
- Placebo Drug
- gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 6, 2011
- Primary completion
- Dec 11, 2012
- Completion
- Dec 11, 2012
- Last update posted
- Jul 15, 2024
2011 – 2012
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fullerton | California | 92835 | — |
| Research Site | La Jolla | California | 92093-0957 | — |
| Research Site | Los Angeles | California | 90095-1772 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Rancho Mirage | California | 92270 | — |
| Research Site | Redondo Beach | California | 90277 | — |
| Research Site | Santa Maria | California | 93454 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Harvey | Illinois | 60426 | — |
| Research Site | Quincy | Illinois | 62301 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Bend | Oregon | 97701 | — |
| Research Site | Providence | Rhode Island | 02903 | — |
| Research Site | Providence | Rhode Island | 02906 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Knoxville | Tennessee | 37909 | — |
| Research Site | Fort Worth | Texas | 76177 | — |
| Research Site | Paris | Texas | 75460-5004 | — |
| Research Site | Abingdon | Virginia | 24211 | — |
| Research Site | Spokane Valley | Washington | 99216 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01231347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2024 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01231347 live on ClinicalTrials.gov.